Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by GenericAdvocateon Sep 17, 2016 1:51pm
100 Views
Post# 25248446

RE:RE:RE:odds of developing a drug to commercial stage 5000-1

RE:RE:RE:odds of developing a drug to commercial stage 5000-1TraderBen,  While I have been concentrating on how Concordia is jacking up prices on their North American drugs, I found this action in the article you put up scummier than what Valeant did !!!   And then they say its a new drug launch?  This will be added to all the class action suits that Concordia has against them if it hasn't been already.  Unbelievable! 

" ...Manchester and Lincolnshire issued separate documents highlighting sharp increases in the price of old drugs after a new drug company acquired them and dropped existing brand names.

Price rises have led to the NHS encouraging doctors to take patients off at least one drug, the thyroid treatment liothyronine. Its price has risen from 16p to £9.22 per tablet, including from £1.23 per tablet three years ago, and a typical patient takes at least one or two tablets a day.

The drug has a single supplier, AMCo, which has said the product is “incredibly difficult to manufacture” and needs significant investment to en-sure a steady supply. A spokeswoman for AMCo, now known as Concordia International, did not respond to a request for comment on the legislation."



<< Previous
Bullboard Posts
Next >>